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Abstract
Background: The glycosylphosphatidylinositol-anchored extracellular membrane serine protease prostasin is
expressed in normal bladder urothelial cells. Bladder inflammation reduces prostasin expression and a loss of
prostasin expression is associated with epithelial-mesenchymal transition (EMT) in human bladder transitional cell
carcinomas. Non-steroidal anti-inflammatory drugs (NSAIDs) decrease the incidence of various cancers including
bladder cancer, but the molecular mechanisms underlying the anticancer effect of NSAIDs are not fully understood.
Methods: The normal human bladder urothelial cell line UROtsa, the normal human trophoblast cell line B6Tert-1,
human bladder transitional cell carcinoma cell lines UM-UC-5 and UM-UC-9, and the human breast cancer cell line
JIMT-1 were used for the study. Expression changes of the serine proteases prostasin and matriptase, and
cyclooxygenases (COX-1 and COX-2) in these cells following ibuprofen treatments were analyzed by means of
reverse-transcription/quantitative polymerase chain reaction (RT-qPCR) and immunoblotting. The functional role
of the ibuprofen-regulated prostasin in epithelial tight junction formation and maintenance was assessed by
measuring the transepithelial electrical resistance (TEER) and epithelial permeability in the B6Tert-1 cells.
Prostasin’s effects on tight junctions were also evaluated in B6Tert-1 cells over-expressing a recombinant
human prostasin, silenced for prostasin expression, or treated with a functionally-blocking prostasin antibody.
Matriptase zymogen activation was examined in cells over-expressing prostasin.
Results: Ibuprofen increased prostasin expression in the UROtsa and the B6Tert-1 cells. Cyclooxygenase-2
(COX-2) expression was up-regulated at both the mRNA and the protein levels in the UROtsa cells by ibuprofen in
a dose-dependent manner, but was not a requisite for up-regulating prostasin expression. The ibuprofen-induced
prostasin contributed to the formation and maintenance of the epithelial tight junctions in the B6Tert-1 cells. The
matriptase zymogen was down-regulated in the UROtsa cells by ibuprofen possibly as a result of the increased
prostasin expression because over-expressing prostasin leads to matriptase activation and zymogen down-regulation
in the UROtsa, JIMT-1, and B6Tert-1 cells. The expression of prostasin and matriptase was differentially regulated by
ibuprofen in the bladder cancer cells.
Conclusions: Ibuprofen has been suggested for use in treating bladder cancer. Our results bring the epithelial
extracellular membrane serine proteases prostasin and matriptase into the potential molecular mechanisms of the
anticancer effect of NSAIDs.
Keywords: Ibuprofen, Prostasin, Matriptase, Cyclooxygenase, Tight junction, Cancer
* Correspondence: lchen@mail.ucf.edu
Burnett School of Biomedical Sciences, University of Central Florida College
of Medicine, 4000 Central Florida Boulevard, Building 20, Room 323, Orlando,
FL 32816-2364, USA
© 2015 Chai et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chai et al. BMC Cancer  (2015) 15:1025 
DOI 10.1186/s12885-015-2039-6
Background
Serine proteases have very diverse functions in biological
and pathological processes, such as blood coagulation,
complement activation, food digestion, blood pressure
regulation, inflammation, and cancer [1]. Prostasin is a
glycosylphosphatidylinositol (GPI)-anchored extracellular
membrane serine protease with broad expression in all
epithelial cells in many tissues and organs including the
prostate, bladder, kidneys, colon, lungs, placenta, and skin
[2]. Prostasin can also be detected in the urine and semen
upon proteolytic shedding from the membrane. In the
past 20 years since the discovery of prostasin [3–5], this
protease has been shown to have important structural
and/or functional roles in placental development, epithe-
lial tight junction formation, epidermal/epithelial terminal
differentiation, epithelial sodium channel activation, blood
pressure regulation, and inflammation [2].
Prostasin has also been implicated for a role in many
cancers including prostate, breast, ovarian, and bladder
cancers. Prostasin expression is reduced in high-grade
prostate cancers as well as in invasive human prostate
and breast cancer cells [6–8] and bladder cancers [9].
But prostasin is over-expressed in the cancerous ovarian
epithelial cells and stroma [10]. A loss of prostasin ex-
pression is associated with epithelial-mesenchymal tran-
sition (EMT) in human urothelial cancer cell lines and
also correlates with the grades of bladder cancer [9]. On
the other hand, re-expression of prostasin in cancer cells
negative for prostasin could suppress tumor invasion
and potentially metastasis [6, 7].
Transcription of the prostasin gene can be regulated by
DNA methylation and histone acetylation [7, 9, 11], aldos-
terone [12], nerve growth factor (NGF, 11), transforming
growth factor- β1 (TGF-β1, [13]), Slug [14], and sterol regu-
latory element-binding proteins (SREBPs) [15]. Further, in a
lipopolysaccharide (LPS)-induced mouse bladder inflamma-
tion model, the prostasin gene expression was down-
regulated and this down-regulation was associated with a
marked increase in the expression of the inducible nitric
oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and
some cytokines [16]. Over-expression of prostasin can at-
tenuate LPS-induced iNOS up-regulation in the mouse
bladder [16] and decrease the expression of iNOS and
COX-2 genes in prostate cancer cells [17]; whereas silen-
cing the prostasin gene expression in human prostate cells
is associated with an induction of iNOS expression [18].
Prostasin can activate the type-II trans-membrane extracel-
lular serine protease matriptase [19], while prostasin can
also be activated reciprocally by matriptase [20]. The prote-
ase activity of prostasin can be regulated by reversible
serine protease inhibitors such as the hepatocyte growth
factor activator inhibitors, HAI-1 and HAI-2 [21, 22], or
the irreversible serine protease inhibitor, protease nexin-1
(PN-1), [11].
Prostasin is normally localized at the apical side of ter-
minally differentiated epithelial cells and is essential for
epithelial tight junction functions [23]. Tight junctions
are membranes joined together from adjacent cells on
the apical end. The joint membranes create an imperme-
able barrier to seal the epithelium and separate the “in-
side” (interstitial space) from the “outside” (lumen or
environment) of the body. The main structural proteins
that constitute the epithelial tight junctions are the
occludins [24] and the claudins [25]. Even though pros-
tasin is required for the formation and functions of the
tight junction, the exact molecular mechanisms of pros-
tasin in this role are not clear, especially in regard to the
epithelial tight junction proteins occludins and claudins.
It is also not perfectly clear how prostasin’s expression
and function are regulated in this role.
LPS can compromise epithelial tight junction and in-
crease permeability via a mechanism dependent on the
toll-like receptor 4 (TLR4) [26]. Prostasin expression is
reduced by LPS [16] while prostasin can proteolytically
cleave the TLR4 ectodomain (ECD) to down-modulate
cellular signaling mediated by this receptor [27]. The
attenuation of LPS-induced inflammatory mediator ex-
pression by forced prostasin expression [16] can poten-
tially be attributed to prostasin’s regulatory role on the
TLR4. Restoring prostasin expression in cells in the
state of inflammation with a compromise of the tight
junction barrier may then work toward restoring the
barrier, in addition to taming the expression of the in-
flammatory mediators. In the clinical setting, prostasin
expression may be manipulated by way of a pharma-
ceutical agent. The non-steroidal anti-inflammatory
drugs (NSAIDs) decrease the incidence of various
cancers including that of the colon, breast, lung and
prostate, but the molecular mechanisms underlying the
anticancer effect of NSAIDs are not fully understood
[28]. The NSAID ibuprofen has been shown to reduce
the survival of bladder cancer cells via the induction of
the p75 neurotrophin receptor (p75NTR), a tumor and
metastasis suppressor [29], and an inducer of prostasin
expression [11]. We sought to investigate if prostasin
can be regulated by ibuprofen in normal human blad-
der urothelial cells and in bladder cancer cells. We also
tested if the ibuprofen-induced prostasin participates in
the formation of epithelial cell tight junction using a
normal human trophoblast cell line. Our study revealed
that prostasin can be up-regulated by ibuprofen, and a
properly regulated level of the prostasin protein in
epithelial cells is critical for maintaining a healthy
epithelial structure and function.
Methods
The immortalized normal human urothelial cell line
UROtsa was kindly provided by Dr. Donald A. Sens of the
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University of North Dakota, School of Medicine (Grand
Forks, ND). The UM-UC-5 and UM-UC-9 human transi-
tional cell carcinoma (TCC) cell lines were kindly pro-
vided by Dr. H. Barton Grossman (MD Anderson Cancer
Center, Houston, TX). The hTERT-immortalized normal
human trophoblast cell line B6Tert-1 was a gift of Dr.
Yanling Wang (Institute of Zoology, State Key Laboratory
of Reproductive Biology, Chinese Academy of Sciences,
Beijing, China). The human breast cancer cell line JIMT-1
was purchased from the German Collection of Microor-
ganisms and Cell Cultures (Braunschweig, Germany). The
cell lines used in this study are publicly available and all
information regarding the cell lines is also publicly avail-
able, and thus are not considered human subjects per
guidelines of the National Institutes of Health (U.S.A).
Plastic dishes and plates including Transwells with 12-
mm 0.45-μM cellulose membranes were purchased from
Corning (Corning, NY, USA). All culture medium and
supplements were purchased from Invitrogen (Carlsbad,
CA). Ibuprofen was purchased from Sigma-Aldrich (St.
Louis, MO). The selective COX-1 inhibitor, FR12047
(Cat# 236005) and the selective COX-2 inhibitor II (cat#
236012) were purchased from EMD Millipore (Millipore,
Billerica, MA). Fluorescein Dextran 3000 MW was pur-
chased from Molecular Probe (ThermoFisher Scientific,
Waltham, MA).
Cell culture and ibuprofen treatment
The UROsta, UM-UC-5 and UM-UC-9 cells were cultured
as described [9]. The normal human trophoblast B6Tert-1
cells were cultured on collagen I-coated dishes as described
[30]. Human breast cancer JIMT-1 cells were cultured in
EMEM medium supplemented with 10 % fetal bovine
serum (FBS), sodium pyruvate, non-essential amino acids,
and vitamins. All cells were incubated at 37 °C in a humidi-
fied atmosphere of 5 % CO2 in air.
Ibuprofen was dissolved in dimethyl sulfoxide (DMSO)
at a concentration of 0.5 M as a stock. Cells were seeded
in or grown to confluence in 12-well plates, and were
treated with ibuprofen at different doses or times. For
the experiments using the B6Tert-1 cells, confluent cul-
tures were treated with 2 mM ibuprofen for 24 h and
were then trypsinized and seeded in 12-mm Transwells
for continued growing and transepithelial electrical re-
sistance (TEER) measurement. DMSO was used as a
solvent control for the ibuprofen treatment.
Establishment of cell lines with prostasin expression-
silencing or prostasin over-expression
Preparations of B6Tert-1 cells with the human prosta-
sin expression silenced using short interfering RNAs
(siRNA) were described previously [30]. Construction
of B6Tert-1 cell lines with a stable over-expression of
prostasin (B6/Pro) or the vector alone (B6/Vec) was
described previously, as well [30]. The expression of
prostasin in the B6/Pro cells is under the control of the
cytomegalovirus (CMV) promoter and is also regulated
by the tet repressor, allowing the induction of prostasin
expression upon the addition of tetracycline (1 μg/ml)
in the culture medium. JIMT-1 cells stably over-
expressing prostasin without the tet repressor (JIMT-1/
Pro) or harboring the vector alone (JIMT-1/Vec) were
constructed using the method described previously
[30]. Transient expression of prostasin in the UROtsa
cells was accomplished by using a lentivirus harboring
the human prostasin cDNA (pLVX-Pro) in the pLVX-
Puro lentiviral vector (Clontech Laboratories, Inc.). A
lentivirus with the pLVX-Puro vector alone was used as
a control.
Western blot analysis
The procedures for western blot analysis were de-
scribed previously [31]. Briefly, after the treatment cells
were washed with PBS and lysed in RIPA buffer for 15–
30 min at 4 °C with rocking. The supernatants were
collected by centrifugation of the cell lysates at 10,000
×g for 10 min. Protein concentrations were determined
using a DC Protein Assay kit (Bio-Rad, Hercules, CA).
Equal amounts of total protein for each sample were
analyzed on SDS-PAGE and electro-transferred to a
nitrocellulose membrane. The membranes were
blocked with 5 % non-fat milk in TBS-T (20 mM Tris-
HCI, pH 7.4, 137 mM NaCl, 0.1 % Tween-20), and in-
cubated with the appropriate primary antibodies at 4 °C
for overnight. On the next day, the membranes were
washed with TBS-T and blotted with an appropriate
secondary antibody conjugated to the horseradish
peroxidase (Promega, Madison, WI) for 1 h at room
temperature. The membranes were then washed again
before an enhanced-chemiluminescence reaction (ECL,
Pierce Biotechnology, Inc., Rockford, IL) and exposed
to X-ray films. The primary antibodies used were
human prostasin (1:4,000, Ref. 3), tubulin (1:5,000,
Sigma-Aldrich), glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH, 1:5,000, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), matriptase (mouse monoclonal, 1:4,000,
Santa Cruz Biotechnology), matriptase (rabbit polyclonal,
1:4,000, Bethyl Laboratories, Inc., Montgomery, TX) and
COX-2 (1:1,000, R&D System, Inc., Minneapolis, MN).
Reverse-transcription and real-time quantitative
polymerase chain reaction (RT-qPCR)
Cells at confluence in a 12-well plate were treated with
ibuprofen at different doses or DMSO for different time
periods. The total RNA was isolated using the TRIzol®
reagent (Invitrogen). The procedures for RT-qPCR ana-
lysis of prostasin, matriptase, COX-2, GAPDH mRNA
expression have been described previously [16, 17]. The
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relative quantity of each gene’s transcript was calculated
using the ΔCt method (Bio-Rad Application Guide) to
normalize to the quantity of the GAPDH transcript.
Transepithelial electrical resistance (TEER) measurement
For the ibuprofen-treated cells: The B6Tert-1 cells were
treated with ibuprofen (2 mM) or DMSO for 24 h and
then trypsinized and seeded at 2 ×105/insert in 12-mm
diameter Transwell inserts. On the next day, the transe-
pithelial electrical resistance (TEER) was measured using
an Epithelial Voltohmmeter (EVOM, World Precision
Instruments, Inc., Sarasota FL). After the measurement,
the ibuprofen-treated cells were treated with either a
prostasin antibody, or a pre-immune rabbit serum (as a
control), or left alone without any treatment. The TEER
was measured every day for 5 days and the medium was
changed every 2 days with the addition of the prostasin
antibody or the pre-immune rabbit serum.
For cells with transient prostasin-silencing: 24 hours
after the transfection of the prostasin siRNA (100
pM) or a random siRNA (100 pM), cells were seeded
at 2 ×105/insert in the Transwell inserts as described
above. The TEER was measured at 24 h after seeding
and every day thereafter for a total of 3 days.
For cells with stable prostasin over-expression: The
B6/Vec and B6/Pro cells were seeded at 2 ×105/insert in
the Transwell inserts as described above. The TEER was
measured every day for 5 days and the medium was
changed every two days. Tetracycline was added at seed-
ing to induce the prostasin expression. Tumor necrosis
factor alpha (TNFα) was added on day 2 after the meas-
urement of TEER to further enhance the CMV promoter
for achieving a higher prostasin expression.
Paracellular flux (permeability) assay
A fluorescein isothiocyanate (FITC)-labelled dextran (MW
3000) was used and the experiments were performed as de-
scribed previously with some modifications [32]. The
B6Tert-1 cells with silenced prostasin expression and the
corresponding control cells were seeded at 2 ×105/insert in
12-mm diameter Transwell inserts. The TEER was moni-
tored every day after the seeding until the TEER reached a
plateau. The FITC-dextran was added to the apical side of
the monolayer cells at a final concentration of 30 μM, and
the culture was incubated for overnight. After the incuba-
tion, 100 μl of the medium were collected from the basal
side of the monolayer cells and used for measuring the in-
tensity of the fluorescence at wavelengths of Ex494/Em520
nanometers using a Cary Eclipse Fluorescence Spectropho-
tometer (Varian, Inc., Walnut Creek, CA, USA). A higher
intensity of the fluorescence in the basal medium corre-
sponds to a greater amount of the FITC-dextran passing
through the paracellular space from the apical side of the
cells to the basal side of the cells.
Statistical analysis
Data are presented as mean ± SD. A statistically signifi-
cant difference among group means was determined by
one-way ANOVA coupled with the TukeyHSD post hoc
test. A statistically significant difference was defined as
when p < 0.05.
Results
Regulation of prostasin expression by ibuprofen
Previously, we have shown that the prostasin expression
is down-regulated in lipopolysaccharide (LPS)-induced
bladder inflammation [16]. Here we investigated if ibu-
profen (IBU), a non-steroidal anti-inflammatory drug
(NSAID), could affect prostasin expression by the in-
flammation/anti-inflammation pathways. The UROtsa
normal human urothelial cells were treated with ibupro-
fen at different doses ranging from 0.25 mM to 2 mM
for 24 h. The expression of prostasin was analyzed at the
mRNA level by means of reverse-transcription/quantita-
tive polymerase chain action (RT-qPCR), and at the
protein level by means of western blotting using a
prostasin-specific antibody. The prostasin expression
was up-regulated by IBU at the high dose (2 mM), at
both the mRNA and the protein levels (Fig. 1a & b). The
up-regulation of prostasin by IBU was not apparent until
16 h after the IBU treatment (Fig. 1c & d). Interestingly,
the prostasin mRNA expression was initially down-
regulated at 1 h after the IBU treatment, with an up-
regulation in the late phase (16–24 h). There however,
was not a corresponding reduction of the prostasin pro-
tein in the early sampling of the IBU-treated cells. This
probably is a reflection of a rather stable half-life of the
prostasin protein present in the cells prior to the IBU
treatment. It is unclear why there was a two-phased
regulation of the prostasin gene expression in response
to the IBU treatment.
Regulation of COX-2 expression by ibuprofen
The basal expression of COX-2 is moderate at the
mRNA level in the UROtsa cells (Fig. 2a, DMSO-
treated, equivalent to 0.6 % of the GAPDH level), and
not detectable at the protein level (Fig. 2b, DMSO-
treated). The COX-2 expression was greatly induced by
IBU in the UROtsa cells (Fig. 2a), up to 12.1 % of the
GAPDH level or at 19.85 fold over the control. The IBU
induction of COX-2 expression was dose-dependent at
both the mRNA and the protein levels. Furthermore, the
COX-2 expression was induced in a time-dependent
manner with the highest increase at 16 h after the IBU
treatment (Fig. 2c). The coincidental time course of
prostasin and COX-2 induction by the IBU treatment
may suggest a causal relationship of the two induced
genes. On the other hand, in a human breast cancer cell
line JIMT-1, prostasin expression was up-regulated by
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1 mM ibuprofen at 24 h of treatment, but without a
significant induction of COX-2 expression (data not
shown), suggesting that the up-regulation of prostasin
expression by IBU does not require a concomitant
COX-2 up-regulation. We also evaluated the COX-1 ex-
pression in the UROtsa cells. The basal expression level
of COX-1 is minimal at less than 0.01 % of the GAPDH
level; and the COX-1 expression was also increased in
response to the IBU treatment, but only marginally to
no more than 0.03 % of the GAPDH level (data not
shown).
Effect of selective COX inhibitors on prostasin expression
Ibuprofen is a non-selective inhibitor of both the COX-1
and COX-2 enzymes. We sought to determine if
ibuprofen’s action on prostasin expression was mediated
by inhibiting either the COX-1 or COX-2 enzyme activity.
The selective COX-1 inhibitor, FR12047 has an IC50 of 28
nM and a ~2300 fold selectivity towards the COX-1 en-
zyme over the COX-2 enzyme. The selective COX-2 in-
hibitor II has an IC50 of 4 nM and a ~28,500 fold
selectivity towards the COX-2 enzyme over the COX-1
enzyme. Both selective COX inhibitors were used for
treating the UROtsa cells as indicated in Fig. 3. Neither in-
hibitor up-regulated prostasin or COX-2 expression.
Effect of prostasin on the transepithelial electrical
resistance
Prostasin is required for maintaining the epithelial barrier
function and for epidermal terminal differentiation [20, 23].
a b
c d
Fig. 1 Effects of ibuprofen on prostasin expression. a & b the UROtsa cells were treated with ibuprofen for 24 h at different dosages as indicated.
a RT-qPCR (n = 3). b western blotting (representative image from three experiments). c & d the UROtsa cells were treated with 2 mM ibuprofen
for different time periods as indicated. c RT-qPCR (n = 3). d western blotting (representative image from three experiments). The numbers above
each bar (a) & (c) indicate the fold change of the expression as compared to the DMSO control. One-way ANOVA and Tukey’s post hoc were used
for data analysis, and p < 0.05 was considered statistically significant. The asterisk denotes p <0.05 between IBU treated and DMSO control cells
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We hypothesized that the ibuprofen-induced prostasin
could help maintain the epithelial barrier integrity by
promoting tight junction formation and maintenance. Such
a functional output can be manifested by an increased
transepithelial electrical resistance (TEER). To evaluate
IBU’s effects on the TEER via prostasin up-regulation, we
chose to use a normal human trophoblast cell line B6Tert-
1 because the B6Tert-1 cells establish tight junctions over
the course of monolayer expansion with a sharper increase
of the TEER giving the assay an increased and requisite
robustness. The UROtsa cells, however, were not able to
form tight junctions with an increase in TEER over the cell
culturing period. As shown in Fig. 4a, compared with the
B6Tert-1 cells treated with DMSO, the B6Tert-1 cells
treated once with 2 mM ibuprofen for 24 h established a
higher TEER and this effect lasted for at least 5 days. An
increased expression of prostasin in the B6Tert-1 cells
following the IBU treatment was confirmed by western
blotting (Fig. 4b, lanes 1–2). The addition of a functionally
blocking prostasin antibody to the ibuprofen-treated cells
however, prevented the TEER increase and counteracted
IBU’s effect (Fig. 4a). The addition of a control pre-immune
rabbit serum did not affect IBU’s effect on the TEER. The
expression of prostasin at the end of the TEER measure-
ments (day 5) was analyzed by western blotting (Fig. 4b,




Fig. 2 Ibuprofen up-regulates COX-2 expression. a & b the UROtsa cells were treated with ibuprofen for 24 h at different dosages as indicated.
a RT-qPCR (n = 3). b western blotting (representative image from three experiments). c RT-qPCR (n = 3), the UROtsa cells were treated with 2 mM
ibuprofen for different periods of time as indicated. The numbers above each bar (a) & (c) indicate the fold change of the expression as compared
to the DMSO control. One-way ANOVA and Tukey’s post hoc were used for data analysis, and p < 0.05 was considered statistically significant.
The asterisk denotes p < 0.05 between IBU treated and DMSO control cells
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due to the addition of the prostasin antibody in the cultur-
ing medium. The reduced prostasin protein level was ac-
companied with a lower TEER as indicated in Fig. 4a.
Transient silencing of the prostasin gene expression by
siRNA in the B6Tert-1 cells also impaired on the TEER
gain (Fig. 4c), underscoring the role of prostasin in main-
taining the integrity of the epithelial tight junction. Reduc-
tion of the prostasin protein expression in the B6Tert-1
cells treated with the prostasin-specific siRNA was con-
firmed by western blotting (Fig. 4d). The change of the
TEER as a result of prostasin expression silencing in the
B6Tert-1 cells was accompanied with a change of perme-
ability to macromolecules. The prostasin-reduced B6Tert-1
cells allowed the FITC-labeled dextran to pass through the
paracellular space from the apical side to the basal side of
the monolayer cells, as indicated by the higher intensity of
fluorescence in the basal medium of these cells whereas the
control cells essentially did not allow the FITC-dextran to
pass through (Fig. 4e). This observation indicates that the
TEER change along with the prostasin expression silencing
was the result of a tight junction compromise.
Previous studies showed that either prostasin knock-
out or over-expression in the mouse skin could impair
the skin epidermal barrier function [23, 33]. In order to
better understand prostasin’s function at the mechanistic
level in tight junction regulation, we studied a stable
B6Tert-1 cell line (B6/Pro) that expresses prostasin




Fig. 3 Selective COX inhibitors did not affect prostasin expression. The UROtsa cells were treated with COX inhibitors for 24 h. IBU: ibuprofen,
2 mM; COX-1(−): COX-1 inhibitor, 10 μM; COX-2(−): COX-2 inhibitor, 10 μM. a & c RT-qPCR (n = 3). The numbers above each bar indicate the fold
change of the expression as compared to the DMSO control. Note: the bars of DMSO and IBU in (a) and (c) are the same of those in Fig. 1a and
Fig. 2a, respectively. One-way ANOVA and Tukey’s post hoc were used for data analysis, and p < 0.05 was considered statistically significant. The
asterisk denotes p < 0.05 between IBU treated and DMSO control cells. b western blotting (representative image from three experiments)
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regulation [30]. Since the CMV promoter activity can be
enhanced by tumor necrosis factor alpha (TNF-α, [34]),
the cells were also treated with TNF-α in some experi-
ments. When the prostasin expression was moderately
induced in the B6/Pro cells with tetracycline (tet, 1 μg/
ml), the cells presented a higher TEER than those
without the tetracycline treatment (Fig. 4f ). However,
when the prostasin expression was further induced with
both tetracycline and TNF-α (5 ng/ml), the B6/Pro cells
had an acute reduction in the TEER; indicating a com-
promised tight junction integrity. The TEER was not
affected in the B6/Vec control cells under similar
Fig. 4 Transepithelial electric resistant (TEER) measurement and permeability assay. The B6Tert-1 cells were first treated with 2 mM ibuprofen for
24 h and seeded in Transwells to develop cell-cell contact and tight junctions. The TEER was measured using an EVOM device as described in the
Methods. a TEER of B6Tert-1 cells treated with DMSO (used as a solvent control), or ibuprofen, or a prostasin antibody (Pro Ab), or a pre-immune
rabbit serum (used as a control). ANOVA: p < 0.05. b Western blot analysis of prostasin expression in B6Tert-1 cells treated with 2 mM ibuprofen
for 24 h (Lanes 1–2); or grown in Transwells for 5 days (Lanes 3–6). c TEER of B6Tert-1 cells treated with a prostasin-specific siRNA. Untreated: cells
were not treated with any reagent; Con siRNA: a random siRNA used as a control; Pro siRNA: the prostasin-specific siRNA; Mock: cells were treated
with the transfection reagent Lipofectamine 2000 only. ANOVA: p < 0.05. d Western blot analysis of prostasin expression in B6Tert-1 cells after
silencing prostasin expression. e Permeability of B6Tert-1 cells to FITC-dextran (n = 3). The prostasin siRNA-treated cells had the most FITC-dextran
in the basal medium of the cells. ANOVA: p < 0.05. f TEER of B6Tert-1 cells expressing different amounts of prostasin. Pro: prostasin; tet: tetracycline;
TNF: tumor necrosis factor (alpha). ANOVA: p < 0.05. g TEER of B6Tert-1 cells harboring the vector alone (Vec). ANOVA: p > 0.05. h Western blot analysis
of prostasin expression in B6Tert-1 under tet or tet + TNF-α treatment. The numbers under each lane indicate the fold change of the expression as
compared to the vector control (Vec)
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treatments, i.e., tetracycline induction alone or in com-
bination with TNF-α (Fig. 4g). Treating the B6/Pro and
B6/Vec cells with TNF-α alone also had no effect on the
TEER (data not shown). The amount of prostasin pro-
tein in the B6/Vec cells and the B6/Pro cells under tetra-
cycline treatment without or with the addition of TNF-α
is shown in Fig. 4h. The TEER changes observed in the
B6/Pro cells can therefore, be attributed to the prostasin
over-expression changes. These results indicate that a
regulated amount of prostasin expressed in the cells is
critical for the establishment and maintenance of the
tight junction; whereas too little or too much prostasin
expression is detrimental to the epithelial tight junction
integrity.
Regulatory interactions between prostasin and matriptase
serine proteases
As prostasin and matriptase regulate each other’s func-
tions reciprocally, we sought to investigate if an ibuprofen
treatment would bring forth accompanying changes in
matriptase expression or function along with the prostasin
expression and function changes. As shown in Fig. 5 in
the UROtsa cells, the matriptase expression was mostly
regulated at the protein level rather than at the mRNA
level by ibuprofen or selective COX inhibitors. The
matriptase mRNA level was not changed (Fig. 5a–c), but
the 95-kDa matriptase zymogen was down-regulated with
increasing doses of ibuprofen in the treatment (Fig. 5d). It
is not clear if ibuprofen directly affected the matriptase
zymogen or indirectly via the increased prostasin protein
expression.
To determine if the increased prostasin can cause a
down-regulation of the matriptase zymogen, we transi-
ently infected UROtsa cells with a prostasin-expressing
lentivirus (pLVX-Pro). The matriptase zymogen is a 95-
kDa type-II membrane protein on epithelial cell mem-
branes. Upon cleavage/activation, the C-terminal serine
protease domain could still be non-covalently linked with
the “stem” part of the matriptase protein and/or the in-
hibitor HAI-1 on the cell membrane; without being re-
leased into the culturing medium [35]. As shown in
Fig. 5e, the left panel; prostasin over-expression caused a
quantity reduction of the 95-kDa matriptase zymogen in
the UROtsa cells, but a quantity increase of a 30-kDa
matriptase fragment recognized by the antibody capable
of recognizing the C-terminal serine protease domain of
matriptase. To determine if this phenotype exists in other
cell lines, we stably over-expressed prostasin in the human
breast cancer cell line JIMT-1 and the B6Tert-1 tropho-
blast cells. Similar results were obtained as shown in
Fig. 5e, the middle and right panels, that upon prostasin
over-expression, the 95-kDa matriptase zymogen was
reduced in quantity but the 30-kDa matriptase protease
domain was increased in quantity. These results indicated
that prostasin may be responsible for the cleavage of the
30-kDa matriptase serine protease domain either directly
or indirectly via another intermediate protease; and the
IBU-induced prostasin could, at least in part, be respon-
sible for the reduced matriptase zymogen expression
shown in Fig. 5d.
We also evaluated the expression level of the hepatocyte
growth factor activator inhibitor type I (HAI-1) in these
cells that over-expressed prostasin, either transiently or
stably. HAI-1 is expressed as a membrane-associated
Kunitz-type protein which binds to and inhibits the activ-
ity of many serine proteases including prostasin and
matriptase. In the prostasin over-expressing UROtsa,
JIMT-1 and B6Tert-1 cells, the quantity of the membrane-
associated HAI-1 protein was increased, possibly as a
result of an increased prostasin expression on the cell
membrane (Fig. 5e). The increased prostasin could
bind more HAI-1 resulting in the retention of HAI-1
on the cell membrane, rather than being secreted into
the culturing medium [36]. The mRNA level of HAI-
1 was not significantly affected in these cells (data
not shown).
Regulation of prostasin expression by IBU in bladder
cancer cell lines
We previously reported that the prostasin expression
was down-regulated in high-grade bladder cancers. A
loss of prostasin expression in bladder cancer cell lines
is associated with epithelial-mesenchymal transition [9].
Here, we examined if IBU can up-regulate prostasin ex-
pression in bladder cancer cell lines. Similar to what was
seen in the UROtsa cells, an up-regulation of the prosta-
sin protein expression and a down-regulation of the
matriptase protein expression in the UM-UC-9 human
bladder cancer cells were observed after an IBU treat-
ment, as shown in Fig. 6. Rather different changes, how-
ever, were observed in the UM-UC-5 human bladder
cancer cells. The prostasin protein expression was de-
creased after the IBU treatment in UM-UC-5, without
accompanying changes of the matriptase expression
(Fig. 6). The results indicated that bladder cancer cells
may respond to ibuprofen treatment differently depend-
ing on whether the specific cancer cells have retained
the proper pathways for the responses seen in the nor-
mal epithelial cells.
Discussion
We reported here that ibuprofen, a non-steroidal anti-
inflammatory drug and a non-selective inhibitor of
cyclooxygenases, up-regulated the prostasin expression
in epithelial cells; and in turn increased the transepithe-
lial electrical resistance (TEER) of the epithelial cells. In
vitro, the TEER change reflects a change in the integrity
of epithelial cell tight junctions since the TEER is
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Fig. 5 (See legend on next page.)
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primarily determined by the apical tight junctions. The
higher the TEER the stronger the tight junctions there
are between epithelial cells. A loss of the barrier integrity
in the epithelium may promote fluid movement from
the interstitial regions into the lumen spaces, or facilitate
the movement of toxic and carcinogenic chemicals from
the lumen through the paracellular passage into the
underlying tissue and blood stream causing further
damages. Therefore, maintaining the intact epithelial
integrity is essential for a healthy body against poten-
tially toxic environmental insults.
The serine protease prostasin plays important roles in
maintaining the integrity of the epithelium via regulating
the tight junctions at the cell-cell contacts [20, 23], in
taming innate epithelial inflammation via attenuating the
expression of inducible nitric oxide synthase (iNOS) in
vivo, and in the regulation of the iNOS and COX-2 gene
expression in vitro [16–18]. If epithelial cells can main-
tain a sufficient prostasin expression under stress such
as an inflammation to help maintain the epithelium in-
tegrity, the damage to the epithelium and the underlying
tissue may be reduced or minimized. Knocking out the
prostasin gene expression in the mouse skin compro-
mised epithelial cell tight junctions leading to a life-
threatening dehydration of the neonatal skin [23]. On
the other hand, over-expression of prostasin in epithelial
cells to or beyond a certain level decreases the TEER
(Fig. 4); which ironically is a phenotype also associated
with a prostasin down-regulation. In our results, either a
reduced or an over-abundant prostasin expression is
detrimental to the epithelium structures and functions
(Fig. 4). It is vital that the prostasin expression level and
its functions are tightly controlled in epithelial cells.
Matriptase intimately interacts with prostasin in the
functional roles at the epithelium and the two proteases
reciprocally activate each other from their respective
zymogens [19, 20, 32]. The matriptase expression was
unaffected by ibuprofen at the mRNA level but its zymo-
gen was down-regulated by ibuprofen. In our model cell
lines, over-expression of a recombinant prostasin alone
was capable of inducing matriptase activation and zymo-
gen down-regulation (Fig. 5e) so the ibuprofen-induced
prostasin may very well be responsible for the matrip-
tase activation and zymogen down-regulation in the
ibuprofen-treated cells. While the increased prostasin
can activate matriptase, it is also possible that the
cognate serine protease inhibitor(s) for both proteases,
e.g., HAI-1, is competed off matriptase by the increased
Fig. 6 Western blot analysis of prostasin and matriptase expression in UROtsa and human bladder transitional cell carcinoma cell lines (UC-9 and
UC-5). The UROtsa cells were treated with 2 mM ibuprofen and cancer cells were treated with 0.5 mM ibuprofen for 24 h. Twenty-five micrograms
of total protein from each sample were loaded in each lane. Samples from two separated experiments were shown. The numbers under each
lane indicated the fold change of the expression as compared to the DMSO control. IBU: ibuprofen. GAPDH was used as a loading control
(See figure on previous page.)
Fig. 5 Effect of COX inhibitors and prostasin on matriptase expression. a & b RT-qPCR (n= 3). The UROtsa cells were treated with different dosages of
ibuprofen for 24 h or at 2 mM ibuprofen for different time periods. c RT-qPCR (n= 3). The UROtsa cells were treated with COX inhibitors for 24 h. IBU:
ibuprofen, 2 mM; COX-1(−): COX-1 inhibitor, 10 μM; COX-2(−): COX-2 inhibitor, 10 μM. a, b, and c The numbers above each bar indicate the fold change
of the expression as compared to the DMSO control. ANOVA: p> 0.05. Note: the bars of DMSO and IBU in (c) are the same of those in (a). d Western blot
analysis of matriptase in UROtsa treated with different dosages of ibuprofen for 24 h as indicated. Note the samples on the membrane were blotted with
the anti-matriptase antibody after blotting with anti-COX-2 and anti-tubulin antibodies shown in Fig. 2b. The previously blotted COX-2 protein bands is
shown along with the matriptase protein bands. eWestern blot analysis of prostasin, matriptase, HAI-1 expression in stable or transient prostasin
over-expressing cell lines as indicated. Vec: vector control; Pro: prostasin over-expressing lines
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prostasin. In other words, the dynamic of the protease-
inhibitor network, prostasin ↔ HAI-1 ↔ matriptase, is
tipped in favor of matriptase to be more active. A re-
duced HAI-1 availability to inhibit matriptase will en-
hance matriptase auto-activation and the activated
matriptase will activate more prostasin. Our current re-
sults are consistent with that of a previous study [32] in
which either the co-expression of prostasin and matrip-
tase in the presence of the inhibitor HAI-1 or the
addition of a recombinant prostasin to the Caco-2 cells
could generate the 30-kD active matriptase protease
domain. A keenly balanced regulation of the two serine
proteases, prostasin and matriptase, and their inhibitor,
HAI-1 would therefore be important for maintaining
intact epithelial tight junctions.
Prostasin expression was down-regulated by ibuprofen
at 1 h after the treatment in the UROtsa cells. A recent
report by Lichtenberger et al. [37] revealed that ibupro-
fen could interact with phosphatidylcholine to transi-
ently change cell membrane physical properties leading
to increased cell permeability. Such a mechanism of ac-
tion would lead to a condition that mimics a transient
inflammation-like state in the UROtsa cells. Conse-
quently, prostasin expression was reduced as a response
to this “inflammation mimicry”. Alternatively, the
ibuprofen-phospholipid interaction could affect cell sig-
naling pathways that lead to the down-regulation of the
prostasin expression in the early phase of the ibuprofen
treatment. Whether an early down-regulation of prosta-
sin by ibuprofen is mediated by such pathways requires
further investigation.
In vitro, the level of prostasin expression changes with
the cell density, i.e. a lesser prostasin expression in
sparsely-cultured cells and a higher prostasin expression
in densely-cultured cells (Chen, unpublished results). In
vivo, a proper prostasin expression is indispensable for the
placenta labyrinth maturation, during the differentiation
of cytotrophoblasts to syncytiotrophoblasts [38–40].
Furthermore, prostasin expression is often lost in poorly
differentiated cancers. These results suggested that prosta-
sin is expressed less in proliferating cells but expressed
more in differentiating cells. Treating epithelial cells with
the anti-inflammatory drug ibuprofen may trigger the cell
repair/differentiation signaling pathways, resulting in
prostasin expression up-regulation. The response of epi-
thelial cells to an ibuprofen treatment varies depending on
the cell type and the cell states, i.e., in a proliferating state
or a repair/differentiation state. It would follow simply
from the view point of prostasin expression regulation by
ibuprofen that only certain cancer patients with certain
types of cancer would benefit from taking ibuprofen as an
adjuvant treatment.
Ibuprofen at a high dose up-regulates prostasin ex-
pression and in turn increases the TEER. Even though
there was a significant increase of COX-2 expression
along with the up-regulation of prostasin, it is unlikely
that the increased COX-2 expression caused the increase
of prostasin expression since in the JIMT-1 cells there
was an increased prostasin expression by ibuprofen
without an accompanying induction of COX-2 (data not
shown). At least, the COX-2 induction is not a requisite
for the prostasin induction by ibuprofen and the two
ibuprofen-induced molecular events do not seem to be
coupled.
Ibuprofen is used to reduce inflammation and pain
based on an accepted mechanism of inhibiting cyclooxy-
genases. But other indications have been proposed for
ibuprofen, such as its use as an anti-cancer agent. The
molecular mechanisms for such indications may be far
less defined and may have very little to do with COX in-
hibition. A recent study by Sun et al. [41] suggested that
phosphor-ibuprofen (P-I, MDC-917), a derivative of ibu-
profen, has an anti-cancer function via the regulation of
oxidative stress and redox homeostasis involving the Trx
system. Breast cancer cells treated with P-I had an in-
creased level of oxidized Trx-1 and a reduced thiore-
doxin reductase (TrxR) activity. The downstream
changes were a suppressed NF-κB activity and activated
p38 and JNK kinase cascades. The P-I’s anti-cancer ac-
tivity is Trx-1-dependent since Trx-1 knockdown dimin-
ished the P-I’s anti-cancer activity. Prostasin has not
been studied in the context of oxidative stress nor iden-
tified as a player in the Trx system. Prostasin, however,
is an inflammatory “negative” protein and down-
regulated during inflammation, but up-regulated by the
anti-inflammatory drug ibuprofen. Prostasin has been
suggested to inhibit tumor invasion and metastasis, and
prevent epithelial-mesenchymal transition. Epidemio-
logical studies have shown that ibuprofen reduces the
progression and recurrence of various types of cancers
[28]. It is reasonable to propose that up-regulating pros-
tasin expression by ibuprofen may be a mechanism of
ibuprofen in its anti-cancer action.
Previously, we have shown that prostasin promoter
methylation was a mechanism for the reduced expres-
sion of prostasin in bladder cancer cells. The prostasin
gene promoter is minimally heterogeneously methylated
in the UM-UC-9 and unmethylated in the UM-UC-5 at
a site critical for prostasin expression and both cell lines
express a high level of prostasin [9]. The prostasin pro-
moter in the UM-UC-9 appeared to be significantly
more active than that in the UM-UC-5 when the prosta-
sin mRNA transcripts were evaluated in these cell lines
[9], suggesting that mechanisms other than promoter
methylation be at play for the prostasin transcriptional
activity. The more active prostasin promoter in the UM-
UC-9 is thus responding to the ibuprofen treatment in
the current study with the observed up-regulation. De-
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methylation and/or histone deacetylase (HDAC) inhib-
ition can reactivate the prostasin promoter as we have
shown for various cancer cells [7, 9, 11]. De-methylation
and/or HDAC inhibition agents may be required prior
to ibuprofen intervention to reactivate and up-regulate
prostasin in bladder cancer cells presenting hypermethy-
lation of the prostasin promoter.
Conclusion
Prostasin expression must be tightly regulated in the
epithelium to maintain a proper barrier function of the
tissue. The NSAID Ibuprofen regulates prostasin expres-
sion and function in epithelial cells, and reduces the
progression and recurrence of certain cancers. Our
results bring the epithelial extracellular membraneserine
proteases prostasin and matriptase into the potential
molecular mechanisms of the anticancer effect of
NSAIDs.
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